色甘酸钠混悬气雾剂与茶碱缓释胶囊治疗中度哮喘的比较

８４例中度哮喘病人分成２组。色甘酸钠组（男性２３例，女性２０例，年龄２６±ｓ８ａ）吸入色甘酸钠混悬气雾剂１０．５ｍｇ，ｔｉｄ。茶碱缓释胶囊组（男性２２例，女性１９例，年龄２７±８ａ）口服０．２５ｇ。ｂｉｄ。２组均连续观察３ｍｏ。结果：色甘酸钠在减轻病人慢性症状、改善肺功能和降低气道高反应性等方面优于茶碱缓释胶囊，（Ｐ＜０．０１）。而后药仅可缓解近期症状。     

液相色谱测定隐形眼镜保护药水中EDTA二钠和山梨酸钾的含量

采用反相高效液相色谱法,以0.02mol/L硼砂为流动相,YNG C_(16)H_(37),为固定相,检测波长288nm,测定隐形眼镜保护药水中EDTA二钠和山梨酸钾的含量。简便快速,结果准确可靠。回收率100.26％(EDTA)、100.36％(山梨酸钾)。相对标准偏差0.85％(EDTA)、0.41％(山梨酸钾)。     

Oral Disodium Cromoglycate Treatment of A topic Dermatitis

Fourteen adults and 10 children with active atopic dermatitis entered this double blind cross-over study of oral disodium cromoglycate (DSCG) (adults 200 mg qid, children 100 mg qid) compared with placebo. Oral DSCG and placebo were given for 6 weeks in random order. According to the investigators' assessments of eczema, significant differences between active and placebo were found after 6 weeks' treatment, DSCG being favoured (P less than 0.05). No differences were detected in the investigators' assessment of lichenization and overall disease. No significant differences between the two treatments were demonstrated in the patients' assessments. Results from food allergic patients were similar to those from non-food allergic patients. Two patients reported possible side effects of arthralgia and urticaria respectively. There were no treatment effects on serum IgE values or any other laboratory data.     

Disodium cromoglycate versus diet in the treatment and prevention of nickel-positive pompholyx

In some cases that have been diagnosed as contact allergy to nickel, there are repeated cutaneous eruptions of pompholyx, even in areas with no direct contact with the metal. The possible alimentary origin of dyshidrotic eczema should be considered when deciding on therapy. We have collected the clinical data for 24 patients with dyshidrotic eczema caused by nickel, to evaluate the benefit of a low-nickel diet versus treatment with oral disodium cromoglycate, comparing both objective and subjective symptoms. A low-nickel diet does not improve these patients but those treated with DSCG reacted better, from both objective and subjective point of view, than either the controls or the patients treated by diet. We next did intestinal permeability tests before therapy and after 15 days of treatment. We found that nickel uptake diminishes simultaneously with the reduction of absorption through the smaller aqueous "pores". This phenomenon was greatest after DSCG. We suggest that DSCG can help selected cases of pompholyx.     

头孢地嗪钠的合成研究

研究第三代头孢菌素头孢地嗪钠的适合工业化生产的制备工艺，即7-氨基头孢烷酸(7-ACA)与2-(2-氨基噻唑-4-基)-(顺式)-2-甲氧亚胺乙酰硫代苯并噻唑活性酯(5)在二氯甲烷于5℃反应4h生成头孢噻肟酸(3)。收率90％，3在水-丙酮溶液中碳酸钠存在下与2-巯基-4-甲基．5-噻唑乙酸(4)在55～60℃反应4h生成头孢地嗪酸(2)，收率66．3％，最后2与异辛酸钠丙酮溶液在低温反应成盐得到头孢地嗪钠(1)，收率89．7％。三步反应总收率53．5％。所得产品含量99．5％(HPLC)。     

Functional MR cholangiography of the cystic duct and sphincter of Oddi using gadoxetate disodium: Is a 30‐minute delay long enough?

Purpose:

To determine if excreted contrast is consistently visualized in the gallbladder and duodenum after a 30‐minute delay using gadoxetate disodium‐enhanced MRI in patients without hepatobiliary disease.

Materials and Methods:

Twenty‐two patients without evidence of liver or biliary disease underwent gadoxetate disodium‐enhanced magnetic resonance imaging (MRI) from February 17, 2009 through October 3, 2011. The mean age was 45 years (range 25–72). T1‐weighted hepatobiliary phase images at 5, 10, 20, and 30 minutes after contrast injection were reviewed in consensus by two radiologists to determine the delay at which enhancement of the gallbladder and duodenum first occurred.

Results:

Thirteen of 22 (59.1%) patients demonstrated duodenal filling by 20 minutes and 16/22 (72.7%) filled by 30 minutes. The mean time to duodenal enhancement was 19.9 minutes (range 11.4–30.2 min). Seventeen of 22 (77.3%) patients demonstrated gallbladder filling by 20 minutes and 21/22 (95.5%) filled by 30 minutes. The mean time to gallbladder enhancement was 16.5 minutes (range 4.4–30.2 min).

Conclusion:

A significant number of normal patients do not show duodenal filling by 30 minutes, while the majority fill the gallbladder by 30 minutes using functional MR cholangiography (fMRC) with gadoxetate disodium. These findings will guide fMRC protocol design for patients with suspected acute cholecystitis and sphincter of Oddi dysfunction. J. Magn. Reson. Imaging 2013;37:993–998. © 2012 Wiley Periodicals, Inc.     

氯屈膦酸二钠联合化疗治疗多发性骨髓瘤的溶骨眭病变的疗效观察

目的探讨氯屈膦酸二钠（clodronate disodium，商品名固令）联合化疗治疗多发性骨髓瘤（multiple mveloma，MM）的溶骨性病变的疗效。方法治疗组20例予氯屈膦酸二钠2400mg／日口服，同时予MP或M2方案化疗；对照组予MP或M2方案化疗。骨痛的缓解和血钙的下降作为评价指标。结果治疗组和对照组用药前均有骨痛，治疗后，治疗组完全缓解7例，部分缓解9例，有效率80％；对照组完全缓解2例．部分缓解6例，有效率44．4％，治疗组有效率高于对照组（P=0．023）。治疗组血钙升高7例，治疗后均降至正常范围，下降率为100％；对照组血钙升高5例，治疗后仅2例降至正常范围，下降率为40％。毒副作用方面，两组病人在用药过程中均未见有严重不良反应，病人耐受性良好。结论氯屈膦酸二钠是一种治疗多发性骨髓瘤伴骨痛和高钙血症的有效药物。     

枸地氯雷他定片联合复方甘草酸苷片治疗慢性荨麻疹的临床疗效

目的研究枸地氯雷他定片联合复方甘草酸苷片对慢性荨麻疹的影响。方法在2017年3月~2019年5月期间,选取124例于某院收治的慢性荨麻疹患者为研究对象,随机分为观察组和参照组,各62例。观察组采取枸地氯雷他定片联合复方甘草酸苷片治疗,参照组采取单纯的枸地氯雷他定片治疗,对比两组患者的治疗总有效率、细胞因子和抗体Ig E水平、治疗结束后6个月和12个月时的复发率。结果经治疗,观察组的治疗总有效率明显高于参照组,数据对比差异具有统计学意义(P<0.05)。另外对两组患者的细胞因子和抗体Ig E水平进行对比,治疗前差异无统计学意义(P>0.05);治疗结束后再次对比,数据有差异(P<0.05)。最后分别对比治疗结束后6个月和12个月时的复发率,数据有差异(P<0.05)。结论采取枸地氯雷他定片联合复方甘草酸苷片治疗慢性荨麻疹的临床疗效极佳,各项实验室指标皆有改善,复发的概率较低,有应用价值。     

荨麻疹汤联合枸地氯雷他定片治疗慢性荨麻疹临床疗效观察

目的观察荨麻疹汤联合枸地氯雷他定片治疗慢性荨麻疹的方法以及临床疗效。方法 120例慢性荨麻疹患者,随机分成治疗组和对照组,每组60例。对照组给予枸地氯雷他定片口服治疗,治疗组在对照组基础上加用自制荨麻疹汤治疗。比较两组临床疗效、不良反应发生情况。结果治疗组治疗总有效率93.3%明显高于对照组的76.7%,差异具有统计学意义(P<0.05)。治疗组发生轻度嗜睡、口干6例(10.0%),对照组发生轻度嗜睡、口干4例(6.7%),比较差异无统计学意义(P>0.05),且均不影响后续治疗,停药后症状缓解。结论荨麻疹汤联合枸地氯雷他定片治疗慢性荨麻疹临床疗效好,值得推广应用。     

注射用三磷酸胞苷二钠有关物质检验方法的建立

目的:建立注射用三磷酸胞苷二钠(CTP-Na2)有关物质检验方法。方法:采用高效液相色谱法,以C18为填充柱,以含反相离子对试剂的磷酸盐缓冲液为流动相[0.02 mol·L^-1磷酸盐缓冲液-乙腈(90∶10)];流速:1.0 mL·min^-1;检测波长:271 nm;柱温:35℃,采用校正因子计算有关物质。结果:CTP-Na 2在0.093~1.860 mg·mL^-1范围内,溶液的浓度与峰面积的线性关系良好,r=0.9997;平均回收率为99.6%(RSD=1.5%,n=9),CTP-Na2对照品溶液在25 h内的稳定性良好(RSD=0.7%);CTP-Na2及主要降解杂质二磷酸胞苷二钠(CDP-Na2)、单磷酸胞苷二钠(CMP-Na2)的方法定量限分别为4.1、2.1、2.8 ng,检出限分别为0.82、0.16、0.22 ng。结论:现行质量标准中有关物质项存在诸多问题,新建的检测方法操作简便、灵敏度高,可用于质量控制。